Last reviewed · How we verify
Sublingual Tizanidine HCl — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Sublingual Tizanidine HCl (Sublingual Tizanidine HCl) — Teva GTC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sublingual Tizanidine HCl TARGET | Sublingual Tizanidine HCl | Teva GTC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sublingual Tizanidine HCl CI watch — RSS
- Sublingual Tizanidine HCl CI watch — Atom
- Sublingual Tizanidine HCl CI watch — JSON
- Sublingual Tizanidine HCl alone — RSS
Cite this brief
Drug Landscape (2026). Sublingual Tizanidine HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/sublingual-tizanidine-hcl. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab